The Neuromuscular Disease Network for Canada

funder-logos_nmd4c

Kathryn Selby

kathy-selby

Clinical Assistant Professor, Pediatric Neurologist, Department of Pediatrics, Faculty of Medicine, University of British Columbia

Medical Director, Pediatric Neuromuscular Program of BC and the Yukon. Investigator at BC Children’s Hospital Research Institute

Email Kathryn

Read more about Kathryn

Biography

Dr Kathryn Selby is a pediatric neurologist who is involved in acute and chronic clinical care as well as academic and research commitments in neurological and neuromuscular disorders.

Kathryn trained in St. Andrews and Manchester Universities in the UK and subsequently at the University of British Columbia and is the medical director of the pediatric neuromuscular program of British Columbia and the Yukon.

Her main areas of specialist interest are pediatric neuromuscular disorders including spinal muscular atrophy and Duchenne muscular dystrophy and she is involved with neurogenetics and knowledge translation. She plays an active role in medical education and was the former program director for the pediatric neurology program at UBC.

She has also partnered with Doctors of BC and has been involved in the development of long-term care plans for muscle specific disorders in the challenging area of transition of care from pediatric to adult care in children with complex neurological and neuromuscular disorders.
She is actively involved with clinical trials in neuromuscular disorders and in patient advocacy.

In the NMD4C network Kathryn is involved with developing and updating of clinical care guidelines and working with the team for implementation and dissemination and piloting of these guidelines. She is also developing a patient advocacy training module and will support knowledge translation within the neuromuscular community.

Recent publications

White, Z, Hakim, CH, Theret, M, Yang, NN, Rossi, F, Cox, D et al.. High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia. J Clin Lipidol. 2020. PMID:32593511

Tarailo-Graovac, M, Zahir, FR, Zivkovic, I, Moksa, M, Selby, K, Sinha, S et al.. De novo pathogenic DNM1L variant in a patient diagnosed with atypical hereditary sensory and autonomic neuropathy. Mol Genet Genomic Med. 2019.7 (10)e00961 PMID:31475481

Deguise, MO, Baranello, G, Mastella, C, Beauvais, A, Michaud, J, Leone, A et al.. Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. Ann Clin Transl Neurol. 2019.6 (8)1519-1532 PMID:31402618

Haijes, HA, de Sain-van der Velden, MGM, Prinsen, HCMT, Willems, AP, van der Ham, M, Gerrits, J et al.. Aspartylglycosamine is a biomarker for NGLY1-CDDG, a congenital disorder of deglycosylation. Mol. Genet. Metab. 2019.127 (4)368-372 PMID:31311714

Demos, M, Guella, I, DeGuzman, C, McKenzie, MB, Buerki, SE, Evans, DM et al.. Diagnostic Yield and Treatment Impact of Targeted Exome Sequencing in Early-Onset Epilepsy. Front Neurol. 2019.10 434 PMID:31164858

See more on PubMed